

Next generation sequencing: From bench to bedside

Gourja Bansal

Premas Life Sciences Pvt. Ltd., New Delhi, India

Correspondence: Premas Life Sciences Pvt. Ltd., New Delhi 110020, Email gourja@premaslifesciences.com

Received: November 10, 2017 | **Published:** November 14, 2017

Copyright© 2017 Bansal. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Next Generation Sequencing (NGS) is a powerful platform that has enabled sequencing of thousands to millions of DNA molecules simultaneously. NGS allows for a large number of genes to be captured and sequenced in parallel, generating an enormous amount of data in a relatively short period of time at much lower cost “per gene”. Labs around the globe are using NGS to examine multiple disease associated alterations in parallel, resulting in a lower cost and faster turnaround time compared to single gene assays. NGS is

revolutionizing multiple fields including personalized medicine, genetic diseases, and clinical diagnostics. IlluminaTruSight cardio panel provides a comprehensive workflow solution of 174 genes with known associations to 17 inherited cardiac conditions (ICC), including cardiomyopathies, arrhythmias, aortopathies, and more. The fast, easy workflow requires low sample input for simultaneous multigene analysis, saving time and money and providing a highly efficient solution to ICC genetic profiling.